Glucagon-like peptide-1 (GLP-1) agonists have garnered significant public interest over the past year, partly due to celebrities using them and posting on social media. However, many patients fare equally well losing weight through lifestyle modifications and less expensive medications such as phentermine, experts from Kaiser Permanente said at AMCP 2024, in New Orleans. They discussed assorted utilization management techniques to ensure GLP-1 agonists are deployed appropriately.
A